8-K: Bicara Therapeutics Advances Pivotal Study with Positive Phase 1b Data

Bicara Therapeutics announced preliminary Phase 1b expansion cohort data for ficerafusp alfa plus pembrolizumab, showing high response rates and advancing pivotal study dose selection.

Summary

• Bicara Therapeutics presented preliminary Phase 1b expansion cohort data for 750mg of ficerafusp alfa weekly in combination with pembrolizumab in first-line human papillomavirus-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) at the European Society for Medical Oncology Asia Congress (ESMO Asia) on December 6, 2025.
• The 750mg dose demonstrated a 57% confirmed overall response rate (ORR) (17/30 patients), with 10% (3/30) achieving a complete response (CR) and 29% (5/17) of responders showing deep responses of at least 80% tumor shrinkage.
• The combination was generally well-tolerated, with a safety profile consistent with the known profile of ficerafusp alfa plus pembrolizumab in R/M HNSCC, and no treatment-related deaths were reported.
• New biomarker data indicated that 1500mg of ficerafusp alfa yielded a greater increase in TGFinhibition within the tumor microenvironment and greater immune activation compared to the 750mg dose.
• This increased TGFinhibition at 1500mg translated to a median depth of response of 82% (with 64% of responders achieving a deep response) versus 63% (with 27% of responders achieving a deep response) at the 750mg dose at 24 weeks.
• The totality of the data suggests that a higher dose of ficerafusp alfa with greater TGFinhibition and immune activation drives deeper tumor responses that translate to more durable outcomes for patients.
• The company plans to declare the optimal biologic dose for use in the pivotal FORTIFI-HN01 study in the first quarter of 2026.

Sentiment

Score: 8

Explanation: The preliminary Phase 1b data for ficerafusp alfa in combination with pembrolizumab shows strong efficacy signals, including high overall response rates, complete responses, and deep tumor shrinkage, particularly at the higher dose. The manageable safety profile and Breakthrough Therapy Designation further de-risk the pivotal FORTIFI-HN01 study and position the company favorably for future development and potential accelerated approval in a high unmet need indication.

Positives

• High confirmed overall response rate (ORR) of 57% (17/30) with the 750mg dose of ficerafusp alfa plus pembrolizumab in first-line HPV-negative R/M HNSCC.
• Significant complete response (CR) rate of 10% (3/30) and deep responses (>=80% tumor shrinkage) in 29% (5/17) of responders at the 750mg dose.
• The combination was generally well-tolerated with a manageable safety profile, consistent with previous observations, and no treatment-related deaths.
• Biomarker data supports a dose-dependent increase in TGFinhibition and immune activation, leading to deeper and potentially more durable responses at higher doses (1500mg vs. 750mg).
• Breakthrough Therapy Designation granted by the U.S. FDA for ficerafusp alfa in combination with pembrolizumab for first-line R/M HNSCC (HPV-negative, CPS >=1).
• The data advances pivotal study dose selection, with an optimal dose declaration expected in Q1 2026, further derisking the FORTIFI-HN01 study.
• Ficerafusp alfa is a first-in-class bifunctional EGFR-directed antibody x TGFligand trap, addressing a significant unmet medical need in HPV-negative R/M HNSCC.

Risks

• Uncertainties inherent in the development of product candidates, including the conduct of research activities and clinical trials.
• Uncertainties as to the availability and timing of results and data from clinical trials.
• Whether results from prior preclinical studies, preliminary or interim data from earlier stage clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials.
• Regulatory developments in the United States and foreign countries.
• Whether cash resources will be sufficient to fund foreseeable and unforeseeable operating expenses and capital expenditure requirements.
• Risks and uncertainties identified in filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the year ended December 31, 2024, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• Ability to establish and maintain collaborations, strategic relationships and supply arrangements, or that intended benefits from such relationships or arrangements will not be realized.
• Ability to raise additional funding on favorable terms, or at all.
• The rate and degree of market acceptance and clinical utility of product candidates.
• Ability, and the ability of collaborators, to protect intellectual property and to conduct activities for the development and commercialization of candidates in view of third-party intellectual property positions.
• Financial performance.
• Ability to retain and recruit key personnel.
• Developments and projections relating to competitors or the industry.
• Changes in general economic conditions and global instability.
• Changes in laws and regulations.

Future Outlook

The company anticipates declaring the optimal biologic dose for the pivotal FORTIFI-HN01 study in the first quarter of 2026. This dose selection is expected to advance the trial towards an interim analysis and potential accelerated approval, followed by potential full approval, aiming to deliver deep and durable responses for patients with HPV-negative R/M HNSCC.

Management Comments

• "Ficerafusp alfa, the first and only bifunctional EGFR-directed antibody x TGFligand trap, was purposefully designed to deliver deep and durable responses with the potential to meaningfully extend overall survival for patients."
• "The data presented today mark an important advancement in our dose-optimization strategy, reinforce our confidence in the interim overall response rate analysis as the foundation for pursuing accelerated approval in the FORTIFI-HN01 pivotal trial, and further elucidate the relative contribution of TGFin driving deep and durable tumor responses."
• "We have made significant progress in the FORTIFI-HN01 trial this year and are on track to declare an optimal dose in the first quarter of 2026."

Industry Context

Head and neck squamous cell carcinoma (HNSCC) is a significant and growing cancer type, with HPV-negative recurrent/metastatic HNSCC representing approximately 80% of cases and carrying a worse prognosis. This patient population exhibits high rates of therapeutic resistance and a critical unmet need for therapies that can deliver durable anti-tumor responses. Ficerafusp alfa, as a first-in-class bifunctional EGFR-directed antibody x TGFligand trap, is designed to overcome inadequate tumor penetration, a major barrier in treating solid tumors like R/M HNSCC, by reversing the fibrotic and immune-excluded tumor microenvironment.

Comparison to Industry Standards

• Ficerafusp alfa (1500mg QW) + Pembrolizumab demonstrated an Objective Response Rate (ORR) of 54% in HPV-negative R/M HNSCC patients (CPS >=1), which is significantly higher than historical ORRs of 19% for Pembrolizumab monotherapy and 36% for Pembrolizumab + chemotherapy.
• The median Overall Survival (mOS) for Ficerafusp alfa (1500mg QW) + Pembrolizumab was 21.3 months in HPV-negative R/M HNSCC patients (CPS >=1), more than double the historical mOS of approximately 9 months for Pembrolizumab alone and 7 months for Pembrolizumab + chemotherapy in HPV-negative patients.
• The complete response (CR) rate for Ficerafusp alfa (1500mg QW) + Pembrolizumab was 21%, substantially higher than the 5% CR rate observed with Pembrolizumab monotherapy.
• The 750mg dose of Ficerafusp alfa + Pembrolizumab achieved a 57% ORR, also significantly higher than historical controls for Pembrolizumab monotherapy (19%) and Pembrolizumab + chemotherapy (36%).
• The median Duration of Response (mDOR) for Ficerafusp alfa (1500mg QW) + Pembrolizumab was 21.7 months, which compares favorably to Pembrolizumab + chemotherapy (6.7 months), though slightly less than Pembrolizumab monotherapy (23.4 months) in the broader HPV-all population from the KEYNOTE-048 trial.

Stakeholder Impact

• Shareholders: Positive clinical data and advancement towards pivotal trial de-risk the investment and could lead to increased share price.
• Patients: Potential for a new, highly effective treatment option for a challenging and high unmet need cancer (HPV-negative R/M HNSCC).
• Medical Community: New data provides insights into the efficacy and safety of ficerafusp alfa, potentially influencing future treatment paradigms.
• Employees: Positive clinical progress can boost morale and confidence in the company's pipeline.

Next Steps

• Declare the optimal biologic dose for use in the pivotal FORTIFI-HN01 study in the first quarter of 2026.
• Conduct longer follow-up to assess durability and other longer-term efficacy parameters for the 750mg dose.
• Continue the FORTIFI-HN01 pivotal Phase 2/3 clinical trial in patients with first-line R/M HNSCC.

Key Dates

Recommendation

The preliminary Phase 1b data for ficerafusp alfa in combination with pembrolizumab demonstrates compelling efficacy, with significantly higher overall response rates, complete response rates, and median overall survival compared to historical controls for standard-of-care treatments in a challenging patient population (HPV-negative R/M HNSCC). The dose-dependent biomarker and response depth data provide strong mechanistic support. Coupled with Breakthrough Therapy Designation and a manageable safety profile, these results substantially de-risk the ongoing pivotal FORTIFI-HN01 study and indicate a high probability of clinical and commercial success, warranting a strong buy recommendation for long-term investors.

Keywords

Bicara Therapeutics, BCAX, ficerafusp alfa, pembrolizumab, HNSCC, head and neck squamous cell carcinoma, oncology, clinical trial, Phase 1b, ESMO Asia, TGF-beta, EGFR, biopharmaceutical, Breakthrough Therapy Designation, FORTIFI-HN01